标题/作者	年份
Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) PD Tamma, SL Aitken, RA Bonomo, AJ Mathers, D Van Duin, CJ Clancy Clinical Infectious Diseases 72 (7), e169-e183	2021
Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options CC Sheu, YT Chang, SY Lin, YH Chen, PR Hsueh Frontiers in microbiology 10, 80	2019
Antibiotics in the clinical pipeline in October 2019 MS Butler, DL Paterson The Journal of antibiotics 73 (6), 329-364	2020
Antibiotic resistance breakers: current approaches and future directions M Laws, A Shaaban, KM Rahman FEMS microbiology reviews 43 (5), 490-516	2019
New β-lactam–β-lactamase inhibitor combinations D Yahav, CG Giske, A Grāmatniece, H Abodakpi, VH Tam, L Leibovici Clinical microbiology reviews 34 (1), 10.1128/cmr. 00115-20	2020
Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections PD Tamma, SL Aitken, RA Bonomo, AJ Mathers, D Van Duin, CJ Clancy Clinical infectious diseases 74 (12), 2089-2114	2022
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection M Castanheira, PJ Simner, PA Bradford JAC-antimicrobial resistance 3 (3), dlab092	2021
Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections B Suay-García, MT Pérez-Gracia Antibiotics 8 (3), 122	2019
Considerations and caveats in combating ESKAPE pathogens against nosocomial infections YX Ma, CY Wang, YY Li, J Li, QQ Wan, JH Chen, FR Tay, LN Niu Advanced Science 7 (1), 1901872	2020
Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter S Dhingra, NAA Rahman, E Peile, M Rahman, M Sartelli, MA Hassali, ... Frontiers in Public Health 8, 535668	2020
Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-β-lactamases SJ Hecker, KR Reddy, O Lomovskaya, DC Griffith, D Rubio-Aparicio, ... Journal of medicinal chemistry 63 (14), 7491-7507	2020
Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting S Morris, E Cerceo Antibiotics 9 (4), 196	2020
Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria Y Liu, R Li, X Xiao, Z Wang Critical reviews in microbiology 45 (3), 301-314	2019
Resistance to ceftazidime–avibactam and underlying mechanisms Y Wang, J Wang, R Wang, Y Cai Journal of global antimicrobial resistance 22, 18-27	2020
β-lactam/β-lactamase inhibitor combinations: an update KHME Tehrani, NI Martin Medchemcomm 9 (9), 1439-1456	2018
Treatment options for colistin resistant Klebsiella pneumoniae: present and future N Petrosillo, F Taglietti, G Granata Journal of clinical medicine 8 (7), 934	2019
The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update D Reynolds, M Kollef Drugs 81 (18), 2117-2131	2021
Emerging therapies against infections with Pseudomonas aeruginosa B Tümmler F1000Research 8	2019
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems S Karakonstantis, EI Kritsotakis, A Gikas Infection 48 (6), 835-851	2020
Carbapenemases in Enterobacteriaceae: detection and antimicrobial therapy X Cui, H Zhang, H Du Frontiers in microbiology 10, 1823	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。